Last edition
News about
Pharmaceutical Contract Manufacturing Market Size to Hit USD 140 Billion by 2030 Say, Roots Analysis
It is estimated to grow at a compounded annual growth rate of 6.5% during the forecast period (2022-2030).
Clearview Cancer Institute Partners with OneOncology to Expand Cancer Care Access in Alabama
This strategic partnership, marking Clearview Cancer Institute as the 20th practice to integrate with OneOncology, is geared towards elevating cancer care services across Alabama.
India Advocates Swift USFDA Inspections at the 14th Trade Policy Forum
The Indian delegation is expected to strongly advocate for expediting USFDA inspections of domestic pharmaceutical firms.
Swiss Firm SHL Medical Acquires US-based Superior Tooling Inc. to Boost Manufacturing Capabilities
With two new manufacturing sites underway in North Charleston, SC, USA, and Zug, Switzerland, complementing the existing facilities in Taiwan, SHL strategically addresses the growing demand in the autoinjector market.
AIRS Medical Attains CE Certification for SwiftMR Under EU Medical Device Regulation
This certification allows AIRS Medical to sell its flagship product, 'SwiftMR™,' across the EU (27 countries), Turkey, EEA (Liechtenstein, Iceland, Norway), Great Britain, and Switzerland.
BioPulse Solutions Marks its Inaugural Year with INR 360 Million Valuation
BioPulse Solutions Pvt Ltd., announces significant milestones and achievements at the start of 2024 as it continues to bring in innovations in bioprocessing technologies that would significantly benefit the biopharma industry.
Contract Packaging Predicted to See High Growth in 2024 Ahead of Pharmapack Europe
The new survey results are announced ahead of this month’s Pharmapack Europe 2024 (January 24/25th) – held at the Paris Expo, Porte de Versailles (Hall 7.2) – where more than 5000 attendees and 370 exhibitors are expected.
Supriya Lifescience Attains Prestigious GMP Certification from ANVISA Brazil
This milestone is poised to expedite and streamline the registration process for the company’s remaining APIs, facilitating a smoother pathway for their introduction into the Brazilian market.
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for therapeutic product development, manufacturing and commercialization for all human indications worldwide.
AbbVie and Umoja Biopharma Announce Strategic Collaboration
AbbVie and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, have announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVec platform.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy